Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avai Bio (AVAI) Capital Expenditures (2019 - 2020)

Avai Bio's Capital Expenditures history spans 3 years, with the latest figure at $122550.0 for Q4 2020.

  • For Q4 2020, Capital Expenditures changed N/A year-over-year to $122550.0; the TTM value through Dec 2020 reached $122817.0, up 8087.8%, while the annual FY2021 figure was $114.0, 200.0% up from the prior year.
  • Capital Expenditures for Q4 2020 was $122550.0 at Avai Bio, up from $601.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $122550.0 in Q4 2020 and bottomed at -$25838.0 in Q4 2018.
  • The 3-year median for Capital Expenditures is $243.5 (2020), against an average of $16413.2.
  • The largest YoY upside for Capital Expenditures was 107.6% in 2020 against a maximum downside of 107.6% in 2020.
  • A 3-year view of Capital Expenditures shows it stood at -$25838.0 in 2018, then soared by 105.81% to $1500.0 in 2019, then soared by 8070.0% to $122550.0 in 2020.
  • Per Business Quant, the three most recent readings for AVAI's Capital Expenditures are $122550.0 (Q4 2020), $601.0 (Q3 2020), and -$220.0 (Q2 2020).